Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19
- Conditions
- COVID-19
- Interventions
- Procedure: blood sampling
- Registration Number
- NCT04367662
- Lead Sponsor
- University Hospital, Rouen
- Brief Summary
Coronavirus COVID-19 is an emerging virus also called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Eighty percent of patients are poor or asymptomatic. However, there are major respiratory complications for some patients, requiring intensive care hospitalization and possibly leading to death in 5% of cases. One of the hypotheses put forward is that much of the pathophysiology is due to endothelial dysfunction associated with disseminated intravascular coagulation.
The covid-19 pathology could induce coagulation impairment as observed during sepsis. An increase in D-dimer levels during covid-19 disease is itself associated with excess mortality. While D-dimers are highly sensitive, they are not specific for clotting activity. They may be increased in many other circumstances, particularly in inflammation.
On the other hand, the infection stimulates the release of extracellular vesicles. These vesicles, of multiple cellular origin, are an actor of vascular homeostasis, and participate in the state of hyperactivation of coagulation. They have a major role in the prothrombotic state and the development of coagulopathy associated with sepsis.
The aim of our monocentric prospective study would be to study early and more specific markers of hypercoagulability and markers of routine endothelial dysfunction, as soon as the patient is hospitalized, in order to predict the risk of hospitalization in intensive care.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 99
- Any adult patient admitted to Rouen University Hospital for documented SARS-Cov-2 infection (PCR Test or CT scan)
- Patient who accept to participate to research after reading the information note
- Patient affiliated with Social Security
- Patient under protective guardianship or curatorship
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Patient with COVID-19 infection blood sampling Patient with COVID-19 infection hospitalized in a COVID unit
- Primary Outcome Measures
Name Time Method Factor VIII plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Clinical worsening (yes/no) of the patient during hospitalization in the 15 days from admission D-DIMERS plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Thrombin generation test plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Prothrombin Fragment 1 plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Fibrin monomers plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Antithrombin plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Prothrombin Fragment 2 plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Cross-linked platelets plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Willebrand Factor plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
Microvesicles of platelet plasma levels in blood 1 hour after admission Biological analysis using initial blood sampling
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Rouen University Hospital
🇫🇷Rouen, France